Gastroesophageal Reflux Disease (GERD) Market Report 2026

The gastroesophageal reflux disease (gerd) market size has grown steadily in recent years. It will grow from $5.33 billion in 2025 to $5.46 billion in 2026 at a compound annual growth rate (CAGR) of 2.3%. The growth in the historic period can be attributed to widespread use of antacids and h2 blockers, rising obesity prevalence, high consumption of processed foods, increased clinical diagnosis rates, availability of generic ppis.

The gastroesophageal reflux disease (gerd) market size is expected to see steady growth in the next few years. It will grow to $6.2 billion in 2030 at a compound annual growth rate (CAGR) of 3.3%. The growth in the forecast period can be attributed to growth in minimally invasive reflux procedures, demand for long-term symptom management, innovation in endoscopic devices, rising geriatric population, increased patient awareness. Major trends in the forecast period include rising long-term use of proton pump inhibitors, increased adoption of minimally invasive gerd procedures, growing awareness of lifestyle-based disease management, expansion of endoscopic treatment options, higher diagnosis rates through improved screening.

The growing prevalence of esophageal diseases is expected to drive the expansion of the gastroesophageal reflux disease (GERD) market in the coming years. Esophageal diseases are health conditions that impact the esophagus, the muscular tube connecting the mouth and stomach. Treating these diseases focuses on alleviating symptoms, enhancing quality of life, and preventing complications, ultimately improving overall health and well-being for individuals affected by GERD. For example, in January 2023, the American Cancer Society, a US-based professional organization, reported that approximately 21,560 new cases of esophageal cancer are diagnosed annually in the United States, resulting in 16,120 deaths. Hence, the rising prevalence of esophageal diseases is a key driver for the growth of the GERD market.

Leading companies in the GERD market are emphasizing the launch of innovative treatment devices to maintain their competitive edge. For instance, in April 2023, Laborie Medical Technologies, a US-based medical technology firm, introduced the alpHaONE wireless pH-capsule reflux testing diagnostic system for GERD. This system offers up to 96 hours of monitoring, a compact design with enlarged buttons, and a fail-safe capsule delivery mechanism. It also includes a software application featuring a virtual instruction program and customizable symptom buttons to enhance user experience.

In July 2024, Merit Medical Systems, Inc., a US-based provider of healthcare technologies and medical devices across radiology, cardiology, oncology, and endoscopy, acquired EndoGastric Solutions, Inc. for an undisclosed sum. This acquisition allowed Merit to broaden its minimally invasive endoscopy offerings and strengthen its position in the GERD treatment market. EndoGastric Solutions, Inc., a US-based medical device company, developed and commercialized the EsophyX Z+ system, a transoral incisionless fundoplication device for managing chronic GERD.

Major companies operating in the gastroesophageal reflux disease (gerd) market are GlaxoSmithKline PLC, SRS Life Sciences, Takeda Pharmaceutical Company Limited, AstraZeneca Plc, Reckitt Benckiser Group Plc, Eisai Co. Ltd., Pfizer Inc., Medtronic Plc, Teva Pharmaceuticals, HK inno.N Corporation, Mylan N.V., Johnson & Johnson MedTech, Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Salix Pharmaceuticals Inc.

North America was the largest region in the gastroesophageal reflux disease (GERD) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroesophageal reflux disease (gerd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gastroesophageal reflux disease (gerd) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the gastroesophageal reflux disease market by increasing costs of imported pharmaceuticals, endoscopic devices, and diagnostic equipment. Hospitals and specialty clinics in developed regions are most affected due to reliance on imported drugs and procedures. These tariffs raise treatment costs by increasing medication pricing and procedural expenses for diagnostic and therapeutic endoscopy. However, they support domestic drug manufacturing and medical device production, strengthening regional supply chains for GERD management.

The gastroesophageal reflux disease (gerd) market research report is one of a series of new reports that provides gastroesophageal reflux disease (gerd) market statistics, including gastroesophageal reflux disease (gerd) industry global market size, regional shares, competitors with a gastroesophageal reflux disease (gerd) market share, detailed gastroesophageal reflux disease (gerd) market segments, market trends and opportunities, and any further data you may need to thrive in the gastroesophageal reflux disease (gerd) industry. This gastroesophageal reflux disease (gerd) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gastroesophageal reflux disease (GERD) is a disorder in which stomach acid flows back into the esophagus, leading to irritation and discomfort. Treatment for this condition involves various medical approaches and interventions aimed at managing the symptoms and complications associated with gastroesophageal reflux disease.

The primary drug types for gastroesophageal reflux disease include antacids, proton pump inhibitors, H2 receptor blockers, prokinetic agents, dopamine receptor antagonists, EndoCinch, Stretta, Aspyx, and transoral incisionless fundoplication (TIF). Antacids are medications that neutralize stomach acid by increasing the pH level in the stomach. The treatment options also include both invasive and minimally invasive procedures. These therapies are utilized by a range of end-users, including hospitals, homecare providers, and specialty clinics.

The gastroesophageal reflux disease (GERD) market consists of revenues earned by entities by providing pharmaceutical therapies, surgical procedures and diagnostic tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastroesophageal reflux disease (GERD) market also includes sales of gamma-aminobutyric acid type B receptor agonists and alginate antacids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.